UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 21, 2004
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Nevada 000-49616 88-0488686
--------------------------- ---------------------- ------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
11588 Sorrento Valley Road, Suite 17
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (858) 794-8889
--------------
Not Applicable
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On May 24, 2004, Halozyme Therapeutics, Inc. ("Halozyme") issued a press release
that Kenneth Kelley had been named to its Board of Directors. In addition,
Edward Mercaldo resigned from the Board of Directors. The foregoing is discussed
in greater detail in such press release, a copy of which is filed herewith as
Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
The following Exhibit is filed with this Form 8-K.
Exhibit No. Description
----------- ------------
99.1 Press Release of May 24, 2004, regarding the
appointment of Kenneth Kelley to the Board of
Directors and the resignation of Edward Mercaldo from
the Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HALOZYME THERAPEUTICS, INC.
Date: May 24, 2004 By: /s/ Jonathan E. Lim
-------------------------------------
President and Chief Executive Officer